{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:28:34Z","timestamp":1790681314552,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015103","name":"Japan Racing Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018501","name":"Cancer Research Institute, Kanazawa University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ijpddr.2020.10.004","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T13:09:47Z","timestamp":1602767387000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Nullscript inhibits Cryptosporidium and Toxoplasma growth"],"prefix":"10.1016","volume":"14","author":[{"given":"Fumi","family":"Murakoshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-0796","authenticated-orcid":false,"given":"Tatsuki","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluyomi Stephen","family":"Adeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Nonaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2020.10.004_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1471-2334-9-195","article-title":"High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial","volume":"9","author":"Amadi","year":"2009","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib2","doi-asserted-by":"crossref","first-page":"89S","DOI":"10.1111\/j.1550-7408.1996.tb05015.x","article-title":"Improved purification methods for calf-derived Cryptosporidium parvum oocysts using discontinuous sucrose and cesium chloride gradients","volume":"43","author":"Arrowood","year":"1996","journal-title":"J. Eukaryot. Microbiol."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01738-18","article-title":"Inducible nitric oxide synthase is a key host factor for Toxoplasma GRA15-dependent disruption of the gamma interferon-induced antiparasitic human response","volume":"9","author":"Bando","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ijpddr.2020.10.004_bib5","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/iai.62.5.1761-1767.1994","article-title":"Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion","volume":"62","author":"Bohne","year":"1994","journal-title":"Infect. Immun."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijpddr.2016.12.003","article-title":"Comparative effects of histone deacetylases inhibitors and resveratrol on Trypanosoma cruzi replication, differentiation, infectivity and gene expression","volume":"7","author":"Campo","year":"2017","journal-title":"Int. J. Parasitol. Drugs. Drug. Resist."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib8","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1016\/j.bmc.2014.12.066","article-title":"Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT)","volume":"23","author":"Carrillo","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpddr.2016.12.005","article-title":"Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth","volume":"7","author":"Chua","year":"2017","journal-title":"Int. J. Parasitol. Drugs. Drug. Resist."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib10","doi-asserted-by":"crossref","first-page":"13143","DOI":"10.1073\/pnas.93.23.13143","article-title":"Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase","volume":"93","author":"Darkin-Rattray","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ijpddr.2020.10.004_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijpddr.2015.05.004","article-title":"Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites","volume":"5","author":"Engel","year":"2015","journal-title":"Int. J. Parasitol. Drugs. Drug. Resist."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib13","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1016\/j.celrep.2016.08.005","article-title":"Disruption of the class IIa HDAC corepressor complex increases energy expenditure and lipid oxidation","volume":"16","author":"Gaur","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/infdis\/jix689","article-title":"The existing drug vorinostat as a new lead against cryptosporidiosis by targeting the parasite histone deacetylases","volume":"217","author":"Guo","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1469-0691.2002.00485.x","article-title":"Toxoplasma gondii: transmission, diagnosis and prevention","volume":"8","author":"Hill","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/157.1.1","article-title":"AIDS commentary. Toxoplasmic encephalitis","volume":"157","author":"Luft","year":"1988","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib17","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.11150\/kansenshogakuzasshi1970.65.1614","article-title":"Cryptosporidium diarrhea developing in two Japanese adults, one in AIDS and the other in a normal host","volume":"65","author":"Masuda","year":"1991","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.ijpddr.2020.10.004_bib18","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1128\/AAC.00462-10","article-title":"Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds","volume":"54","author":"Maubon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ijpara.2008.11.012","article-title":"An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes","volume":"39","author":"Rider","year":"2009","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib22","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00436-005-1474-8","article-title":"Gene analysis of Cryptosporidium parvum HNJ-1 strain isolated in Japan","volume":"97","author":"Satoh","year":"2005","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib23","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1128\/AAC.49.2.808-812.2005","article-title":"In vitro antileishmanial activity of nicotinamide","volume":"49","author":"Sereno","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib24","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1645\/GE-1043R.1","article-title":"Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro","volume":"93","author":"Strobl","year":"2007","journal-title":"J. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib25","first-page":"3137","article-title":"A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library","volume":"60","author":"Su","year":"2000","journal-title":"Canc. Res."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ab.2014.06.018","article-title":"Microplate assay for screening Toxoplasma gondii bradyzoite differentiation with DUAL luciferase assay","volume":"464","author":"Sugi","year":"2014","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molbiopara.2006.03.010","article-title":"Histone mediated gene activation in Toxoplasma gondii","volume":"148","author":"Sullivan","year":"2006","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/AAC.42.8.1959","article-title":"Efficacy of nitazoxanide against Cryptosporidium parvum in cell culture and in animal models","volume":"42","author":"Theodos","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bcp.2006.06.004","article-title":"Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells","volume":"72","author":"Tong","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpddr.2020.10.004_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.actatropica.2005.03.004","article-title":"Stage-specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase","volume":"94","author":"Vergnes","year":"2005","journal-title":"Acta Trop."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132072030035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221132072030035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:53:13Z","timestamp":1761922393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221132072030035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":27,"alternative-id":["S221132072030035X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2020.10.004","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nullscript inhibits Cryptosporidium and Toxoplasma growth","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2020.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}